State of Wyoming’s NewAmsterdam Pharma NAMS Stock Holding History

State of Wyoming’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-532	Closed	-$17K	–	2133
2026 Q1	$17K	Sell	532 -69	-11%	-$2.25K	﹤0.01%	1687
2025 Q4	$21.1K	Buy	601 +21	+4%	+$764	﹤0.01%	1689
2025 Q3	$16.5K	Buy	580 +30	+5%	+$719	﹤0.01%	1721
2025 Q2	$9.96K	Buy	+550	New	+$10K	﹤0.01%	1763

Other funds holding NAMS

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

State of Wyoming's NAMS Position: Q2 2026 in Review

State of Wyoming sold out of NewAmsterdam Pharma (NAMS) in Q2 2026, closing a stake of 532 shares — an estimated $17K sold.

State of Wyoming first reported a position in NAMS in Q2 2025 and held it in 4 quarters. The position peaked at $21.1K in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

State of Wyoming reported no remaining NewAmsterdam Pharma position as of Q2 2026 after selling out during the quarter.
State of Wyoming sold 532 NewAmsterdam Pharma shares in Q2 2026, an estimated $17K.
State of Wyoming first reported a position in NewAmsterdam Pharma in Q2 2025 and held it in 4 quarters.
State of Wyoming's NewAmsterdam Pharma position peaked at $21.1K in Q4 2025.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on State of Wyoming's 13F filing for Q2 2026, filed 6 Aug 2026.